Amgen, a biopharmaceutical company, has entered a neuroscience collaboration with Novartis in the areas of Alzheimer's disease and migraine. The collaboration also enables Amgen to focus on the commercialisation of its migraine programmes in the US, Canada and Japan, while leveraging Novartis' strong commercial capabilities in neuroscience throughout Europe and other markets worldwide.
As part of the collaboration, Novartis receives global co-development rights and commercial rights outside of the US, Canada and Japan to the investigative molecules in Amgen's migraine portfolio programme. This includes AMG 334 in phase 3 and AMG 301 in phase 1, as well as an option to commercialise an additional early-stage Amgen molecule in these territories.
The agreement combines each company's BACE (beta-site APP-cleaving enzyme-1) programmes targeting Alzheimer's disease into a global co-commercialisation and co-development arrangement. Novartis' phase 1/2a BACE inhibitor (CNP520) will be the lead molecule and each company's pre-clinical BACE inhibitor programmes will be potential follow-ons. Amgen will make upfront and milestone payments, and will be responsible for disproportional research and development costs for an agreed-upon period followed by a 50/50 cost and profit share arrangement. CNP520 is planned to be included in a pioneering prevention study, in collaboration with the Banner Alzheimer's Institute.
Amgen was the first company to clone the BACE gene and subsequent genetic validation of the BACE target has been confirmed by Amgen subsidiary deCODE Genetics.
Novartis' CNP520 is an oral drug designed to prevent the production of different forms of amyloid and has the potential to prevent, slow or delay the symptoms associated with Alzheimer's disease. It is currently in phase 1/2a trials.
Subscribe to PharmaTutor News Alerts by Email >>
